WARREN, N.J., July 18, 2019 /PRNewswire/ -- Aquestive
Therapeutics, Inc. (NASDAQ:AQST), a specialty pharmaceutical
company focused on developing and commercializing differentiated
products based on its proprietary PharmFilm® technology
to meet patients' unmet needs and solve therapeutic problems, today
announced that it will report results for the second quarter ended
June 30, 2019 and provide a business
update on Wednesday, August 7, 2019
before the market open.
The Company will host an investment community conference call at
8:00 a.m. ET on Wednesday, August 7,
2019. Investors and analysts may participate in the
conference call by dialing (866) 417-5886 from the U.S. and (409)
217-8235 internationally, followed by the conference ID:
9956838.
There will also be a simultaneous, live webcast available on the
Investors section of the Company's website at
https://investors.aquestive.com/events-and-presentations. The
webcast will be archived for 30 days.
About Aquestive Therapeutics
Aquestive Therapeutics is
a specialty pharmaceutical company that applies innovative
technology to solve therapeutic problems and improve medicines for
patients. Aquestive is advancing a late-stage proprietary product
pipeline to treat CNS conditions and provide alternatives to
invasively-administered standard of care therapies. The Company
also collaborates with pharmaceutical companies to bring new
molecules to market using proprietary, best-in-class technologies,
like PharmFilm®, and has proven capabilities for drug
development and commercialization.
Forward-Looking Statement
This press release includes
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Words such as "believe,"
"anticipate," "plan," "expect," "estimate," "intend," "may,"
"will," or the negative of those terms, and similar expressions,
are intended to identify forward-looking statements. These
forward-looking statements include, but are not limited to,
statements about our growth and future financial and operating
results and financial position, regulatory approvals and pathways,
clinical trial timing and plans, the achievement of clinical and
commercial milestones, product orders and fulfillment, short-term
and longer term liquidity and cash requirements, cash funding and
cash burn, business strategies, market opportunities, financing,
and other statements that are not historical facts.
These forward-looking statements are based on our current
expectations and beliefs and are subject to a number of risks and
uncertainties that could cause actual results to differ materially
from those described in the forward-looking statements. Such risks
and uncertainties include, but are not limited to, risks associated
with the Company's development work, including any delays or
changes to the timing, cost and success of our product development
activities and clinical trials; the risks of delays in FDA approval
of our drug candidates or failure to receive approval; the risks
inherent in commercializing a new product (including technology
risks, financial risks, market risks and implementation risks and
regulatory limitations); risk of development of our sales and
marketing capabilities; risk of legal costs associated with and the
outcome of our patent litigation challenging third party at risk
generic sale of our proprietary products; risk of sufficient
capital and cash resources, including access to available debt and
equity financing and revenues from operations, to satisfy all of
our short-term and longer term cash requirements and other cash
needs, at the times and in the amounts needed; risk of availability
of refinancing of existing debt facilities; risk of failure to
satisfy all financial and other debt covenants and of any default;
risk related to government claims against Indivior for which we
license, manufacture and sell Suboxone and which accounts for the
substantial part of our current operating revenues; risks related
to the outsourcing of certain sales, marketing and other
operational and staff functions to third parties; risk of the rate
and degree of market acceptance of our products and product
candidates; the success of any competing products, including
generics; risk of the size and growth of our product markets; risk
of the effectiveness and safety of our products and product
candidates; risk of compliance with all FDA and other governmental
and customer requirements for our manufacturing facilities; risks
associated with intellectual property rights and infringement
claims relating to the Company's products; risk of unexpected
patent developments; the impact of existing and future legislation
and regulatory provisions on product exclusivity; legislation or
regulatory action affecting pharmaceutical product pricing,
reimbursement or access; claims and concerns that may arise
regarding the safety or efficacy of the Company's products and
product candidates; risk of loss of significant customers; risks
related to legal proceedings, including patent infringement,
investigative and antitrust litigation matters; changes in
governmental laws and regulations; risk of product recalls and
withdrawals; uncertainties related to general economic, political,
business, industry, regulatory and market conditions and other
unusual items; and other risks and uncertainties affecting the
Company including those described in the "Risk Factors" section and
in other sections included in the Company's Annual Report on Form
10 K filed with the SEC on March 14,
2019 and in our quarterly reports on Form 10-Q. Given these
uncertainties, you should not place undue reliance on these
forward-looking statements, which speak only as of the date made.
All subsequent forward-looking statements attributable to us or any
person acting on our behalf are expressly qualified in their
entirety by this cautionary statement. The Company assumes no
obligation to update forward-looking statements or outlook or
guidance after the date of this press release whether as a result
of new information, future events or otherwise, except as may be
required by applicable law.
Media inquiries:
Christopher Hippolyte
christopher.hippolyte@syneoshealth.com
212-364-0458
Investor inquiries:
Stephanie Carrington
stephanie.carrington@icrinc.com
646-277-1282
View original content to download
multimedia:http://www.prnewswire.com/news-releases/aquestive-therapeutics-to-announce-second-quarter-2019-financial-results-and-recent-business-highlights-on-august-7-2019-300887620.html
SOURCE Aquestive Therapeutics, Inc.